The World Health Organization (WHO) approved the first vaccine against the MPOX virus (monkeys smallpox).
According to the WHO press release, the MVA-BN vaccine is included in the preliminary qualification list.
The drug was developed by the Danish Biotechnological Company Bavarian Nordic A/S.
mva-Bn can be introduced to people over 18 years of age in the form of a 2-house injection with an interval of 4 weeks.
In accordance with WHO recommendations, the vaccine can be used “for other purposes” of infants, children and adolescents, as well as in pregnant women and people with weakened immunity in outbreaks, when the advantages of vaccination outweigh potential risks. ”
“This first preliminary qualification of the Osopa vaccine is an important step in our struggle with this disease both in the context of the current outbreaks in Africa and in the future,” said General Director of Tedros Adkhan Goebreesus.
Ospes virus mpox
MPOX Ospoos virus is transmitted from rodents, such as mice and proteins, or from infected people. Among the most common causes of infection are to touch the rash on the body, the use of infected clothes, sheets and similar objects, as well as contact with biological fluids.
In 2022, the World Health Organization decided to rename the disease of the Ospop Monkeys in MPOX due to numerous racist statements.